May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
An Intravitreal Sustained-Release Fluocinolone Acetonide Device to Treat Severe Experimental Uveitis
P. Mruthyunjaya; D. Khalatbari; P. Yang; S. Stinnett; M. Hanes; G.J. Jaffe
Author Affiliations & Notes
  • P. Mruthyunjaya
    Ophthalmology, Duke University Eye Center, Durham, NC, United States
  • D. Khalatbari
    Ophthalmology, Duke University Eye Center, Durham, NC, United States
  • P. Yang
    Ophthalmology, Duke University Eye Center, Durham, NC, United States
  • S. Stinnett
    Ophthalmology, Duke University Eye Center, Durham, NC, United States
  • M. Hanes
    Division of Laboratory Animal Resources, Duke University, Durham, NC, United States
  • G.J. Jaffe
    Division of Laboratory Animal Resources, Duke University, Durham, NC, United States
  • Footnotes
    Commercial Relationships  P. Mruthyunjaya, None; D. Khalatbari, None; P. Yang, None; S. Stinnett, None; M. Hanes, None; G.J. Jaffe, Control Delivery Systems, Inc I, C.
  • Footnotes
    Support  Research to Prevent Blindness unrestricted grant to Duke Eye Center
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4215. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      An Intravitreal Sustained-Release Fluocinolone Acetonide Device to Treat Severe Experimental Uveitis
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      P. Mruthyunjaya, D. Khalatbari, P. Yang, S. Stinnett, M. Hanes, G.J. Jaffe; An Intravitreal Sustained-Release Fluocinolone Acetonide Device to Treat Severe Experimental Uveitis . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4215.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Abstract: : Purpose: An intravitreal sustained release fluocinolone acetonide (sr-FA) device has been shown in human subjects to control inflammation in eyes with chronic posterior uveitis and panuveitis. To minimize side effects, devices with the lowest possible effective release-rates are needed. In this study, we determined the efficacy of low release-rate (0.5 µg/day, batch no. RD066, and 0.1 µg/day, batch no. RD065) intravitreal sr-FA devices to inhibit ocular inflammation in a rabbit model of severe uveitis. Methods: A sr-FA device with a release rate of either 0.5 µg/day (n=16) or 0.1 µg/day (n=16) was implanted into the vitreous of the right eye of NZW rabbits fourteen days after a subcutaneous injection of tuberculin antigen. Control animals (n=14) received empty devices. Uveitis was induced with an intravitreal tuberculin antigen injection. A masked observer graded corneal neovascularization, anterior chamber (AC) flare, cell, iris congestion, and vitreous opacity on days 1-7, 9, 16, and 21 after uveitis induction. Animals were sacrificed on days 6 and 9 for aqueous WBC count and protein measurement. Retinal function was evaluated by ERG. Histologic sections of enucleated eyes were studied under light microscopy. Results: By clinical criteria, treated eyes were significantly less inflamed than untreated eyes. Anterior chamber cell, flare and vitreous opacity were significantly reduced (p≤0.02) in both drug implant groups compared with control animals. Overall, inflammation was suppressed to a greater degree with the 0.5 µg/day device compared to the 0.1 µg/day device. Aqueous WBC count, protein concentration, ERG b-wave amplitudes, and histopathologic examination paralleled this clinical assessment. Conclusions: Intravitreal sustained-release fluocinolone devices suppress ocular inflammation in a rabbit model of severe uveitis. A low release-rate device may help to reduce potential side effects such as glaucoma and cataract. The inhibition of inflammation demonstrated with the 0.1 µg/day implant provides the rationale for future human studies with lower release-rate devices than are currently employed in clinical trials. Word count of abstract = 2431

Keywords: uveitis-clinical/animal model 
© 2003, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept